AI assistant
Insight Molecular Diagnostics Inc. — Director's Dealing 2022
Dec 20, 2022
34238_dirs_2022-12-20_95d24098-19be-4ba4-af03-8e43c1561868.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-12-16
Reporting Person: Ross Douglas T. (Former CSO.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-01 | Common Stock, no par value | D | 150000 | — | Disposed | 20317 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-16 | Option to Purchase Common Stock | $1.93 | D | 83334 | Disposed | Common Stock (83334) | Direct | |
| 2022-12-16 | Option to Purchase Common Stock | $5.34 | D | 143438 | Disposed | Common Stock (143438) | Direct | |
| 2022-12-16 | Option to Purchase Common Stock | $1.15 | D | 100000 | Disposed | Common Stock (100000) | Direct | |
| 2022-12-16 | Option to Purchase Common Stock | $1.15 | D | 100000 | Disposed | Common Stock (100000) | Direct |
Footnotes
F1: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining restricted stock units immediately vested on December 16, 2022.
F2: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining options immediately vested and became exercisable as of December 16, 2022.